The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group
Open accessAbstract
Purpose: Minimal residual disease (MRD) before allogeneic stem-cell transplantation was shown to predict outcome in children with relapsed acute lymphoblastic leukemia (ALL) in retrospective analysis. To verify this, the Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster (ALL-REZ BFM) Study Group conducted a prospective trial. Patients and Methods: Between March 1999 and July 2005, 91 children with relapsed ALL treated according to the ALL-REZ BFM 96 or 2002 protocols and receiving stem-cell transplantation in ≥ second remission were enrolled. MRD quantification was performed by real-time polymerase chain reaction using T-cell receptor and immunoglobulin gene rearrangements. Results: Probability of event-free survival (pEFS) and cumulative incidence of relapse (CIR) in 45 patients with MRD ≥ 10 −4 leukemic cells was 0.27 and 0.57 compared with 0.60 and 0.13 in 46 patients with MRD less than 10 −4 leukemic cells (EFS, P = .004; CIR, P < .001). Intermediate-risk patients (strategic group S1) with MRD ≥ 10 −4 leukemic cells (n = 14) had a pEFS of 0.20 and CIR of 0.73, whereas patients with MRD less than 10 −4 leukemic cells (n = 21) had a pEFS of 0.68 and CIR of 0.09 (EFS, P = .020; CIR, P < .001). High-risk patients (S3/4, third complete remission) who received transplantation with an MRD load of less than 10 −4 leukemic cells (n = 25) showed a pEFS and CRI of 0.53 and 0.18, respectively. In contrast, pEFS and CRI were 0.30 and 0.50 in patients who received transplantation with an MRD load of ≥ 10 −4 leukemic cells. Multivariate Cox regression analysis revealed MRD as the only independent parameter predictive for EFS (P = .006). Conclusion: MRD is an important predictor for post-transplantation outcome. As a result, new strategies with modified stem-cell transplantation procedures will be evaluated in ALL-BFM trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
van der Velden, V. H. J., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E. R., Flohr, T., Sutton, R., Cave, H., Madsen, H. O., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404586 · Cited by 701
Self-citationLocatelli, F., Bruno, B., Zecca, M., VanLint, M. T., McCann, S., Arcese, W., Dallorso, S., Bartolomeo, P. D., Fagioli, F., Locasciulli, A., et al. (2000) · PubMed · Cited by 140
Spinelli, O., Peruta, B., Tosi, M., Guerini, V., Salvi, A., ZANOTTI, M., Oldani, E., Grassi, A., Intermesoli, T., Micò, M. C., et al. (2007) · Haematologica · doi:10.3324/haematol.10965 · Cited by 132
Kerst, G., Kreyenberg, H., Roth, C., Well, C., Dietz, K., Coustan‐Smith, E., Campana, D., Kościelniak, E., Niemeyer, C. M., Schlegel, P. G., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05401.x · Cited by 124
Self-citationUzunel, M., Mattsson, J., Jaksch, M., Remberger, M., & Ringdén, O. T. H. (2001) · Blood · doi:10.1182/blood.v98.6.1982 · Cited by 98
Šrámková, L., Mužíková, K., Froňková, E., Krejci, O., Sedláček, P., Formánková, R., Mejstříková, E., Starý, J., & Trka, J. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20794 · Cited by 88
Borgmann‐Staudt, A., Zinn, C., Hartmann, R., Herold, R., Kaatsch, P., Escherich, G., Möricke, A., Henze, G., & von Stackelberg, A. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.09.019 · Cited by 80
Self-citationLang, P., Barbin, K., Feuchtinger, T. F., Greil, J., Peipp, M., Zunino, S. J., Pfeiffer, M. M., Handgretinger, R., NIETHAMMER, D., & Fey, G. H. (2004) · Blood · doi:10.1182/blood-2003-05-1735 · Cited by 55
Self-citationPui, C., Jeha, S., & Kirkpatrick, P. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1724 · Cited by 55
Cited by
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
T cell-engaging therapies — BiTEs and beyond
Goebeler, M.-E., & Bargou, R. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0347-5 · Cited by 644
van Dongen, J. J. M., van der Velden, V. H. J., Brüggemann, M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2015-03-580027 · Cited by 511
Metadata
- Authors
- Bader, P., Kreyenberg, H., Henze, G. H. R., Eckert, C., Reising, M., Willasch, A., Barth, A., Borkhardt, A., Peters, C., Handgretinger, R., Sykora, K.-W., Holter, W., Kabisch, H., Klingebiel, T., & von Stackelberg, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-01-20
- Volume
- 27
- Issue
- 3
- Pages
- 377-384
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157460080
- Cited by
- 357
- References
- 14
- FWCI
- 15.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.